Summary of studies investigating the efficiency of mepolizumab on EGPA patients
| Study | Cases, n | Mepolizumabdose | Observationperiod | OCS doses | OCS discontinuation | Symptom | Remission | Relapse |
|---|---|---|---|---|---|---|---|---|
| Wechsler ME et al. [5] | 136 | 300 mgq4w | 52 weeks | ↓ | - | ↓ (ACQ-6) | 28% | 56% |
| Kitamura N et al. [10] | 6 | None stated | 12 weeks | ↓ (29%) | - | ↓ | - | - |
| Ueno M et al. [11] | 16 | 300 mgq4w | 12 months | ↓ (62%) | 25% | ↓ (BVAS) | 75% | - |
| Canzian A et al. [12] | 51 | 100 or 300 mgq4w | 12 months | ↓ (61%) | - | ↓ (BVAS) | 82% | - |
| Ríos-Garcés R et al. [13] | 11 | 100 or 300 mgq4w | 12 months | ↓ (45%) | 9% | ↓ | - | 27% |
| Nakamura Y et al. [14] | 13 | 100 mgq4w | 12 months | - | - | ↓ (VAS) | - | - |
| Bettiol A et al. [15] | 191 | 100 or 300 mgq4w | 24 months | ↓ | 42% | ↓ (BVAS) | - | 25% |
| Özdel Öztürk B et al. [16] | 25 | 100 or 300 mgq4w | 12 months | ↓ (67%) | - | ↓ | - | - |
| Yamane T et al. [17] | 27 | None stated | 48 weeks | ↓ (80%) | 48% | ↓ (VDI) | - | 4% |
| Nolasco S et al. [7] | 49 | 100 or 300 mgq4w | 24 months | ↓ (75%) | 28% | ↓ | 57% | 30% |
| Matsuno O [18] | 20 | 300 mgq4w | - | ↓ (61%) | 40% | → (ACT) | - | - |
| Ishii T et al. [19] | 118 | 300 mgq4w | 96 weeks | ↓ (71%) | 38% | ↓ | - | 5% |
OCS: oral corticosteroid; ACQ-6: asthma control questionnaire-6; BVAS: Birmingham Vasculitis Activity Score; VAS: visual analogue scale; VDI: vasculitis damage index; ACT: asthma control test; q4w: every 4 weeks; ↓: reduction; →: no change; -: no data
